ArticlePharmacology, biochemistry, and behavior2022
In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists.
Article in Pharmacology, biochemistry, and behavior, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- 4F-MDMB-BICA toxicity: a fatal case and literature review of synthetic cannabinoid fatalities.Forensic science, medicine, and pathology · 2026Review
- Behavioral pharmacology of novel synthetic indazole, indole, and benzimidazole cannabinoids in rodents.Journal of cannabis research · 2026Article
- A Meta-Narrative Review of Channelopathies and Cannabis: Mechanistic, Epidemiologic, and Forensic Insights into Arrhythmia and Sudden Cardiac Death.International journal of molecular sciences · 2025Review
- Latest developments in small molecule analgesics: heterocyclic scaffolds I.Future medicinal chemistry · 2025Review
- Assessment of Abuse Potential of Three Indazole-Carboxamide Synthetic Cannabinoids 5F-ADB, MDMB-4en-PINACA and ADB-4en-PINACA.International journal of molecular sciences · 2025Article
- Virtual library docking for cannabinoid-1 receptor agonists with reduced side effects.Nature communications · 2025Article
- Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists.European journal of pharmacology · 2024Article
- A critical assessment of the abuse, dependence and associated safety risks of naturally occurring and synthetic cannabinoids.Frontiers in psychiatry · 2024Review
- The effects of leptin and cannabinoid CB1 receptor agonist/antagonist in cerebral tissues of epileptic rats.Revista da Associacao Medica Brasileira (1992) · 2024Article
- Role of Cannabinoid Signaling in Cardiovascular Function and Ischemic Injury.The Journal of pharmacology and experimental therapeutics · 2023Review
- Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CBPharmacology research & perspectives · 2023Article
- ΔDrug and alcohol dependence reports · 2023Article
- ΔCardiovascular toxicology · 2023Article
- Article
- The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism.Pharmacology, biochemistry, and behavior · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Synthetic cannabinoid receptor agonists (SCRAs) are novel psychoactive substances that bind to and activate CB
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.